INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

ipopba INmune Bio, Inc. (NASDAQ:INMB) is a clinical-stage biotechnology company developing immunotherapies for cancer and neuroinflammatory conditions like Alzheimer's disease [AD]. The DN-TNF platform targets soluble TNF, reducing inflammation without disrupting beneficial transmembrane TNF functions crucial for immune regulation and neuroprotection. The NK priming platform improves NK cells' ability to identify and eliminate abnormal cells, transforming them into highly functional, memory-like NK cells. I ...